Rmb Capital Management, LLC Bluebird Bio, Inc. Transaction History

Rmb Capital Management, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 26, 2022	SELL	$8.96 - $16.31 $104,814 - $190,794	-11,698 Closed	0 $0
Q3 2021 Oct 20, 2021	SELL	$11.24 - $21.0 $91,628 - $171,192	-8,152 Reduced 41.07%	11,698 $224,000
Q1 2021 May 12, 2021	BUY	$16.59 - $33.89 $329,311 - $672,716	19,850 New	19,850 $598,000
Q4 2020 Feb 11, 2021	SELL	$27.5 - $37.92 $528,137 - $728,253	-19,205 Closed	0 $0
Q3 2020 Nov 10, 2020	BUY	$34.44 - $43.75 $23,729 - $30,143	689 Added 3.72%	19,205 $1.04 Million
Q2 2020 Aug 05, 2020	BUY	$27.12 - $45.97 $502,153 - $851,180	18,516 New	18,516 $1.13 Million
Q1 2020 May 11, 2020	BUY	$26.16 - $63.5 $58,362 - $141,668	2,231 Added 15.57%	16,558 $761,000
Q4 2019 Feb 13, 2020	SELL	$46.96 - $61.67 $14,228 - $18,686	-303 Reduced 2.07%	14,327 $1.26 Million
Q3 2019 Nov 12, 2019	BUY	$59.47 - $93.1 $5,947 - $9,310	100 Added 0.69%	14,630 $1.34 Million
Q2 2019 Aug 13, 2019	SELL	$75.84 - $105.21 $36,024 - $49,974	-475 Reduced 3.17%	14,530 $1.85 Million
Q4 2018 Feb 13, 2019	SELL	$59.1 - $93.26 $30,613 - $48,308	-518 Reduced 3.34%	15,005 $1.49 Million
Q3 2018 Nov 14, 2018	BUY	$88.86 - $117.49 $176,031 - $232,747	1,981 Added 14.63%	15,523 $2.27 Million
Q2 2018 Aug 13, 2018	SELL	$99.64 - $127.59 $572,431 - $733,004	-5,745 Reduced 29.79%	13,542 $0
Q1 2018 May 14, 2018	SELL	$105.8 - $150.94 $1.31 Million - $1.86 Million	-12,337 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$81.25 - $130.7 $548,681 - $882,617	-6,753 Reduced 35.37%	12,337 $2.2 Million
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $1.1 Million - $1.75 Million	19,090	19,090 $2.62 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Rmb Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rmb Capital Management, LLC with notifications on news.